An American pharmaceutical company announced today its vaccine was 94.5%. effective against COVID-19.
Moderna, Inc announced today that trial for its vaccine has met 94.5% efficacy rate in a study that enrolled more than 30,000 participants in the U.S.
Based on this data, Moderna now intends to submit an Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration in the coming weeks.
By the end of 2020, Moderna expects to have approximately 20 million doses of the mRNA-1273 vaccine ready for US.
Moderna said it remains on track to manufacture 500 million to 1 billion doses globally in 2021.
The study is based on the analysis of COVID-19 cases confirmed and adjudicated starting two weeks following the second dose of vaccine.
The 97 COVID-19 cases on which the vaccine was tested included 15 older adults over the ages of 65 and 20 participants identifying as being from diverse communities.
“Preliminary analysis suggests a broadly consistent safety and efficacy profile across all evaluated subgroups,” the company said.
“This is a pivotal moment in the development of our COVID-19 vaccine candidate. Since early January, we have chased this virus with the intent to protect as many people around the world as possible. All along, we have known that each day matters.
This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease,” said Stéphane Bancel, Chief Executive Officer of Moderna
